Piramal Critical Care, an integral business unit of Piramal Enterprises Limited and Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology, have officially launched a co-promotion of two of Cumberland's branded hospital products, Caldolor® and Vaprisol® throughout the United States.
Caldolor (ibuprofen) Injection is the first injectable product approved in this country for the treatment of pain and fever in adults. The brand recently received FDA approval for the management of pain and reduction of fever use in pediatric patients six months and older. Vaprisol is the only injectable brand available to treat hyponatremia, the most common electrolyte imbalance in U.S. hospitalized patients.
Piramal will help expand Cumberland's reach for these products by providing coverage to an additional group of hospitals where Piramal's critical care sales force has existing relationships. The multi-year collaboration will provide expanded sales promotion for the two brands, increased communication to medical professionals, to support patient care throughout the U.S. Cumberland will continue to provide the marketing, national accounts, distribution, and medical support for the brands.
A.J. Kazimi, CEO – Cumberland Pharmaceuticals said: "We welcome Piramal as a co-promotion partner in the U.S. and believe this new collaboration will enhance Cumberland's ability to further advance patient care through the delivery of high quality pharmaceutical products in this country."
Peter DeYoung, CEO - Piramal Critical Care said: "We are pleased to partner with Cumberland to co-promote Caldolor® and Vaprisol® in the United States. With the addition of these important products, we will be able to significantly enhance our offering of critical care solutions which we provide to our valued customers and patients."